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The evolving regulatory landscape for clinical stem cell research is characterized by a 
conflict between the striving for international harmonization and an increasing 
process of global regulatory diversification.1 Attempts of regulatory harmonization 
are exemplified, for instance, by the 2016 Guidelines for Stem Cell Research and 
Clinical Translation by the International Society for Stem Cell Research (ISSCR 
2016), the Advanced Therapy and Medicinal Products (ATMP) Regulation of the 
European Medicines Agency (EMA), or by the ATMP Cluster of the US Food and 
Drug Administration (FDA), EMA and Health Canada (Arcidiacono 2012). These 
processes of harmonization have evolved from a pharmaceutical model of drug 
development and the ideal of Evidence-Based Medicine (EBM), with the multiphase 
randomized controlled trial (RCT) system as methodological gold standard. In parallel 
to these developments, however, discontent with the use of the multi-phase trial 
system for the clinical validation of stem cell-based medicinal product has grown. A 
politics of opposition has emerged that has called for the use of alternative methods 
and forms of evidence, to reduce the costs of clinical testing and to increase access to 
non-systematically proven innovative interventions at an earlier stage. Calls for 
international harmonization in the stem cell field have been undermined too, by 
practical challenges to standardize clinical and cell processing procedures in large-
scale, multi-country trials, which require a complex logistical infrastructure and 
significant financial resources. For academic researchers and small to mid-size 
biotech companies these resources are often not available (Rosemann 2014). Since 
industry involvement in stem cell medicine has remained at a low level, the 
mobilization of resources to take investigational stem cell products or therapies 
                                                        
1 Parts of this contribution have been previously published in: Rosemann A, Bortz G, 
Vasen F, Sleeboom-Faulkner M. Global regulatory developments for clinical stem cell 
research: diversification and challenges to collaborations. Regenerative Medicine. 11(7): 647-
57 (2016). Material from that article is reprinted with permission of Future Medicine.  
through rigorous multi-phase trials, remains typically a challenge. This politics of 
alter-standardization has taken an increasingly global form. Many impulses for 
regulatory change and a shift away from multi-phase trials for stem cell-based 
treatments, have come from Asia, especially from Japan, India, China and South 
Korea (Sleeboom-Faulkner et al. 2016). But opposition to EBM and the multi-phase 
trial system, and calls for the emerging of new models and methodologies of clinical 
innovation in the stem cell field has also increasingly evolved in the European Union 
and the USA. These clashes have resulted in three central dynamics of regulatory 
diversification. These developments challenge the use of multi-phase trial 
methodology as the central methodological instrument for therapy development in the 
stem cell field in many respects.  
 
The emerging of a growing number of regulatory exceptions and exemptions 
 
A first dynamic is the emerging of a growing number of regulatory exceptions and 
exemptions, which have been introduced by regulatory authorities in high-income 
countries, especially in the European Union and the USA (Faulkner 2016, Knoepfler 
2014). Examples from the European Union are the “hospital exemption scheme”, 
which has evolved as part of the EMA ATMP regulation, the “conditional approval 
scheme” and the “compassionate use program”. The “hospital exemption scheme”, as 
has widely been documented, allows for the provision of cellular therapies and 
medicinal products to individual patients “under the exclusive professional 
responsibility of a doctor” (source). According to Salter, Zhou and Datta, this scheme 
has provided “the opportunity for a legal market of authorized stem cell therapy 
products to emerge within the province of the clinical professionalism” (Salter, Zhou 
and Datta 2014: 359). The “conditional approval scheme”, on the other hand, allows 
for market approval of a medicinal product at a later stage of a phase III trial, when 
data collection for efficacy and safety has almost been completed (Faulkner 2016). 
Compassionate use” program, in turn, allows access to medicinal products outside of 
phase III premarket clinical trials (Mittra et al. 2015). The “conditional approval 
scheme” and the “compassionate use program” are both part of EMA’s 
pharmaceutical products regulation, but can also be applied to stem cell-based 
medicinal products (Faulkner 2016). While the hospital exemption scheme is unique 
to the European Union, the US FDA has introduced a range of similar regulatory 
exceptions that aim (i) to speed up the transition from preclinical to clinical testing 
(the FDA “fast track approval” scheme), (ii) to realize more rapid authorization of 
phase I and II clinical trials, especially for trials that involve seriously ill patients with 
low life expectancy (the “accelerated approval” scheme), and (iii) to provide access to 
investigational new treatments parallel to FDA-approved phase II and III clinical 
trials (“compassionate use program”) (Knoepfler 2014). The 21st Century Cure Act, 
that was approved by the US Congress in December 2016, has introduced additional 
options to accelerate market approval of new medicines, by offering possibilities to 
avoid going through rigorous, large-scale phase III trials (Kesselheim and Avorn 
2016) and by promoting methodological alternatives to the multi-phase trial system 
such as adaptive and other new trial designs (Butler and Valentine 2016). What this 
growing number of regulatory exceptions and exemptions share is, that they either 
allow to shortcut the clinical trial process, or in some cases, permit possibilities for 
clinical innovation and sometimes commercial clinical applications outside of the 
multiphase trial system, but still within the confines and review procedures of national 
regulatory agencies. Another development in the USA has been a growing number of 
“right-to-try” legislation, which offer patients and physicians the choice to use not-yet 
approved investigational drugs (including cellular medicines) entirely outside of the 
regulatory control of the FDA (Bianco and Sipp, 2014; Darrow et al., 2015). These 
right-to-try laws have now been issued in more than 30 US states (Feibel 2017). 
 
The flexible enforcement of regulatory standards 
 
A second process of regulatory diversification is the flexible enforcement of 
regulatory rules in some countries, that enables the continued provision of 
experimental for-profit interventions with stem cells outside of the review and control 
structures of regulatory agencies. This has happened for various years in India and 
China, where governments responded only gradually to a flourishing grey-area market 
of stem cell therapies (Sleeboom-Faulkner and Patra 2011; Sleeboom-Faulkner et al. 
2016; Sleeboom-Faulkner 2016). Unapproved for-profit therapies continue to be 
tolerated in these countries also after the introduction of national regulatory 
frameworks, which formally prohibit stem cell interventions outside of formally 
approved clinical trials. In China, the 2015 Regulation for Clinical Stem Cell 
Research has explicitly stated that the clinical translation of stem cell-based 
approaches must occur through systematic clinical studies, which must follow from 
sound pre-clinical evidence (Rosemann and Sleeboom-Faulkner 2016). The core of 
this regulation is that stem cell trials can only be conducted in specifically authorized 
research hospitals and that for-profit applications of experimental stem cell 
interventions are legally prohibited (ibid.). Also in India, the 2013 Guidelines for 
Stem Cell Research (and previously in 2007 the Guidelines for Stem Cell Research 
and Therapy) have formally prohibited the use of stem cells in human patients, except 
in the context clinical trials approved by India’s health authorities (Viswanathan et al. 
2013; Indian Council of Medical Research 2013). Despite these formal regulatory 
prohibitions, however, large private hospitals and medical corporations have 
continued to offer their services on the Internet in both countries. In China various 
private clinics and companies continue to advertise stem cell treatments on the world-
wide-web, including on English language websites that aim to attract international 
patients. Also in India, numerous stem cell clinics have an online presence and 
advertize to stem cell-based interventions for a broader range of conditions.  
However, the toleration of unapproved stem cell therapies has by no means 
been restricted to middle-income countries, but it could also be observed in the USA. 
In the USA, the FDA took for several years a surprisingly relaxed approach to clinics 
that have offered autologous stem cell interventions to patients, which have sprouted 
all over the country during the last 8-10 years. According to research conducted in 
2015, there are at present more than 350 US private clinics and businesses offering 
direct-to-consumer stem cell interventions to medical consumers, which have not 
been authorized by the US FDA. These interventions did not only include autologous 
stem cell treatments, but also interventions with autologous stem cells from multiple 
sources, and at least one clinic claimed to offer even human embryonic stem cell-
based interventions (Turner and Knoepfler 2016). With a growing number of right-to-
try laws in the USA and recent regulatory changes introduced by the 21st Century 
Cures Act, and further changes announced by the current Trump government, this 
large number of clinics can be expected to expand rather than to be clamped down.  
 
The abandoning of the multiphase trial system 
 
A third process of regulatory diversification in the stem cell field is characterized by 
the complete abandoning of the multiphase trial EBM system. This has recently 
happened in Japan and steps into this direction have with the 21st Century Cure Act 
also been initiated in the USA. In Japan, the Japanese regulators passed the 
Regenerative Medicine Promotion Act (RMP Act) in 2013 (Government of Japan 
2013). This Act formed the beginning of a far-reaching regulatory reform. The RMP 
Act was followed by an amended Pharmaceuticals Affairs Law, which went into 
effect late 2014 (Government of Japan 2014). Under the amended PAL, the regulatory 
conditions for the clinical testing and use of stem cell-based medicinal interventions 
were significantly transformed (Azuma 2015). The amended law allowed for 
conditional, limited-term market approval of stem cell products after early-phase 
clinical trials. Conditional approval can occur after positive clinical data from as few 
as ten patients (Cyranoski 2013) provided these first-in-human trials demonstrate that 
the tested cell products are safe and ‘likely to predict efficacy’ (Sipp 2015). Once the 
Japanese Pharmaceuticals and Medical Devices Agency has provided conditional 
approval for a stem cell intervention, clinical trial sponsors have the possibility to 
seek conditional market approval for up to 7 years (ibid.). Clinical efficacy is then 
tested in this time period in the context of postmarketing procedures, which can but 
do not have to include rigorous, multiphase trials (source). According to Sipp (2015), 
this evolving regulatory model in Japan has dramatically relaxed the need to 
demonstrate the clinical utility of cellular products prior to marketing, and raises 
critical questions regarding the testing of safety and treatment efficacy. As Sipp has 
pointed out, with this new approach “Japan clearly hopes to compete and succeed in 
the race to build a regenerative medicine industry by flattening a few hurdles” (Sipp 
2015: 355). It is not unlikely that other countries will follow the Japanese regulatory 
model, or at least create additional types of regulatory exceptions in which 
(conditional) market approval of stem cell therapies can be granted without preceding 
phase I‒III trials. In fact, exactly this has now happened in the USA. The passing of 
the 21st Century Cure Act in December 2016 has introduced various steps into a post-
RCT world in the stem cell field, and in other emerging areas of medicine research. 
As Kesselheim and Avorn have stated, advocates have praised the Act as a ‘means of 
speeding drug development’ and to decrease ‘the cost and duration of drugs and 
devices development (Kesselheim and Avorn 2016). This has involved the provision 
of various provisions that have been designed to ‘reduce the amount and rigor of 
clinical testing before new drugs and devices can be approved for use’ (ibid.). These 
include the use of alternative, less rigorous forms of evidence, such as observational 
data and self-reporting of “patient experience” that were previously deemed as too 
subjective and unacceptable in the context of FDA approval procedures (Butler and 
Valentine 2016; Kesselheim and Avorn 2016). Many of the regulatory changes 
introduced by the 21st Century Cure Act will also apply to stem cell treatments, but it 
remains to be seen how applications for specific types of stem cell-based 
interventions are handled in practice.  
  
Conclusions 
 
The regulatory changes and developments introduced in the previous sections 
represent a gradual shift away from a pharmaceutics-oriented model of drug 
developments, that was based on the EBM and multiphase RCT system, and that has 
shaped the regulation of stem cell research in its initial phase, at least in the context of 
the European Union and the USA, but also in many other countries (Rosemann et al. 
2016). Alternative methods and forms of evidence are now step-wise accepted in 
many parts of the word and are likely to partly replace the multiphase trial model for 
the approval of stem cell-based interventions, as well as approval procedures in other 
evolving fields of medicine research. Whether this development will be to the 
ultimate benefit of patients, as many advocates of the 21st Century Cure Act in the 
USA (and advocates of similar changes in various other countries) have claimed, 
remains to be seen. Some would probably argue that it is not, and that the current 
politics of alter-standardization, which is shaped by powerful economic and political 
interests, does misuse the desire of patients for more affordable and more rapidly to 
access cures, by justifying potentially dubious research and irresponsible business 
practices. Others would possibly say that the growing acceptance of less rigorous 
standards and data do in fact increase health risks for patients as well as risks for 
potential forms of financial exploitation. This in turn, could undermine trust in 
science and medicine at a broader level. Still others would probably reason that many 
of the regulatory changes that have been introduced in this paper, diminish hard-won 
ethical and methodological achievements, which have aimed to safeguard patients 
from potential misuse by the medical profession. No matter where you stand in these 
debates, it seems safe to say that the line between the realization of new benefits and 
opportunities for patients and the emerging of new risks, dangers and injustices is 
thin. The regulatory changes described in this paper require for that reason long-term 
monitoring, to obtain a clear idea of their implications for patients and health care 
systems.  
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